{"id":1229,"date":"2026-04-05T14:03:11","date_gmt":"2026-04-05T14:03:11","guid":{"rendered":"https:\/\/www.curedm.co.uk\/?page_id=1229"},"modified":"2026-04-05T14:57:42","modified_gmt":"2026-04-05T14:57:42","slug":"current-dm-research","status":"publish","type":"page","link":"https:\/\/www.curedm.co.uk\/?page_id=1229","title":{"rendered":"Current DM Research"},"content":{"rendered":"\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-group alignwide has-custom-colour-1-background-color has-background has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<p class=\"has-text-align-center\">It is an exciting time for research into Myotonic Dystrophy. From &#8216;in the lab&#8217; to patient trials, there is more happening now than ever before. <\/p>\n\n\n\n<p class=\"has-text-align-center\">CureDM regularly updates a &#8216;Medication Snapshot&#8217; which you can <a href=\"https:\/\/www.curedm.co.uk\/?page_id=741\" data-type=\"page\" data-id=\"741\" target=\"_blank\" rel=\"noreferrer noopener\">view and download here<\/a>.<\/p>\n\n\n\n<p class=\"has-text-align-center\">The headings below will take you to individual research, pharma updates and studies &#8211; please do reach out if you have any questions. CureDM are proud to be a connection between patients and pharma\/trials.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-media-text has-media-on-the-right is-stacked-on-mobile\"><div class=\"wp-block-media-text__content\">\n<p>AMO-02 (tideglusib) is in development for the treatment of congenital myotonic dystrophy and has potential for use in additional CNS, neuromuscular and oncology indications.<\/p>\n<\/div><figure class=\"wp-block-media-text__media\"><a href=\"https:\/\/www.curedm.co.uk\/?page_id=1251\"><img loading=\"lazy\" decoding=\"async\" width=\"230\" height=\"80\" src=\"http:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/logo_amopharma.jpg\" alt=\"\" class=\"wp-image-1249 size-full\"\/><\/a><\/figure><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><a href=\"https:\/\/www.curedm.co.uk\/?page_id=1226\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"327\" height=\"109\" src=\"https:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/Logo_PepGen_FINAL.jpg\" alt=\"\" class=\"wp-image-1223 size-full\" srcset=\"https:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/Logo_PepGen_FINAL.jpg 327w, https:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/Logo_PepGen_FINAL-300x100.jpg 300w\" sizes=\"auto, (max-width: 327px) 100vw, 327px\" \/><\/a><\/figure><div class=\"wp-block-media-text__content\">\n<p>PGN-EDODM1 is a novel, potentially disease-modifying, peptide-conjugated oligonucleotide candidate, currently being studied in patients with myotonic dystrophy type 1 (DM1).<\/p>\n<\/div><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>It is an exciting time for research into Myotonic Dystrophy. From &#8216;in the lab&#8217; to patient trials, there is more happening now than ever before. CureDM regularly updates a &#8216;Medication Snapshot&#8217; which you can view and download here. The headings below will take you to individual research, pharma updates and studies &#8211; please do reach [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":710,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1229","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1229"}],"version-history":[{"count":5,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1229\/revisions"}],"predecessor-version":[{"id":1254,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1229\/revisions\/1254"}],"up":[{"embeddable":true,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/710"}],"wp:attachment":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}